scholarly journals Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib

2017 ◽  
Vol Volume 10 ◽  
pp. 4885-4893 ◽  
Author(s):  
Konstantinos Koutsoukos ◽  
Aristotelis Bamias ◽  
Kimon Tzannis ◽  
Marta Espinosa Montaño ◽  
Vasiliki Bozionelou ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Real World ◽  
Renal Cell ◽  
Cell Cancer ◽  
Line Treatment ◽  
Second Line ◽  
Metastatic Renal Cell Cancer

scholarly journals PCN101 Cost Effectiveness of Everolimus for Second Line Treatment of Metastatic Renal Cell Cancer in Serbia

2012 ◽  
Vol 15 (7) ◽  
pp. A427
Author(s):  
J. Mihajlović ◽  
P. Pechlivanoglou ◽  
A. Sabo ◽  
Z. Tomić ◽  
M.J. Postma
Keyword(s):  
Cost Effectiveness ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Line Treatment ◽  
Second Line ◽  
Metastatic Renal Cell Cancer

An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the ‘Pamerit’ study

2020 ◽  
Author(s):  
Alessandra Mosca ◽  
Ugo De Giorgi ◽  
Giuseppe Procopio ◽  
Umberto Basso ◽  
Giacomo Cartenì ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Renal Cell Cancer ◽  
Real World ◽  
Renal Cell ◽  
Cell Cancer ◽  
Progression Free Survival ◽  
First Line ◽  
Free Survival ◽  
Metastatic Renal Cell Cancer ◽  
Metastatic Rcc

Abstract Objective Despite the current immunotherapy era, VEGFR inhibitors maintain effectiveness in metastatic renal cell cancer. Real-world data concerning pazopanib are limited. The aim of this study is to add information about efficacy and safety of pazopanib as first-line treatment in metastatic renal cell cancer patients not enrolled into clinical trials. Methods Retrospective analysis (the PAMERIT study) of first-line pazopanib in real-world metastatic renal cell cancer patients among 39 Centers in Italy. Outcomes were progression-free survival, overall survival, objective response rate and treatment-related adverse events. Kaplan–Meier curves, log-rank test and multivariable Cox’s models were used and adjusted for age, histology, previous renal surgery, International Metastatic RCC Database Consortium score and pazopanib initial dose. Results Among 474 patients, 87.3% had clear cell metastatic renal cell cancer histology. Most of them (84.6%) had upfront renal surgery. Median progression-free survival and overall survival were 15.8 and 34.4 months, respectively, significantly correlating with International Metastatic RCC Database Consortium’s good prognosis (P < 0.001), ECOG PS 0 (P < 0.001), age (<75 years, P = 0.005), surgery (P < 0.001) and response to pazopanib (P < 0.001). After 3 months of pazopanib, overall disease control rate have been observed in 76.6% patients. Among International Metastatic RCC Database Consortium’s favorable group patients, 57/121 (47%) showed complete/partial response. No unexpected AEs emerged. Conclusions In this real-world study, metastatic renal cell cancer patients treated with first-line pazopanib reached greater progression-free survival and overall survival than in pivotal studies and had high response rates when belonging to International Metastatic RCC Database Consortium’s favorable group, without new toxicities. Pazopanib has been confirmed a valid first-line option for International Metastatic RCC Database Consortium’s good prognosis metastatic renal cell cancer patients who cannot be submitted to immunotherapy.

Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms

2016 ◽  
Vol 35 (4) ◽  
pp. 641-648 ◽  
Author(s):  
C. Rothermundt ◽  
J. von Rappard ◽  
T. Eisen ◽  
B. Escudier ◽  
V. Grünwald ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Cancer ◽  
Line Treatment ◽  
Second Line ◽  
Consensus Algorithms

Prospective front-line management patterns in the Real World Metastatic Renal Cell Cancer (MaRCC) Registry.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e16097-e16097
Author(s):  
Michael Roger Harrison ◽  
Nrupen Anjan Bhavsar ◽  
Steven Paul Wolf ◽  
Brian Addis Costello ◽  
Ulka N. Vaishampayan ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Real World ◽  
Renal Cell ◽  
Cell Cancer ◽  
Front Line ◽  
The Real ◽  
Metastatic Renal Cell Cancer ◽  
Line Management
Sign in / Sign up

Export Citation Format

Share Document